checkAd
    Startseite > Aktien > UroGen Pharma > Nachrichten
    UroGen Pharma Aktie
    12,300
     
    EUR
    -1,60 %
    -0,200 EUR
    Letzter Kurs 31.05.24 Tradegate
    12,100
     
    EUR
    499 STK
    Geldkurs 31.05.24
    12,500
     
    EUR
    479 STK
    Briefkurs 31.05.24
    ISIN: IL0011407140 · WKN: A2DTCV · SYM: UR8 · Israel

    Neueste Nachrichten

    UroGen Pharma to Present at the TD Cowen 5th Annual Oncology Innovation Summit
    22.05.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
    13.05.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Pharma to Participate at Upcoming Investor Conferences
    07.05.24 · Business Wire (engl.) · UroGen Pharma
    New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
    05.05.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
    04.05.24 · Business Wire (engl.) · UroGen Pharma
    New Real-World Study on Retrograde Instillation of JELMYTO for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
    04.05.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
    03.05.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
    17.04.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
    15.04.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
    03.04.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
    14.03.24 · Business Wire (engl.) · UroGen Pharma
    UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    08.03.24 · Business Wire (engl.) · UroGen Pharma